NASDAQ:VVUS - VIVUS Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.18 -0.04 (-0.77 %)
(As of 09/21/2018 12:01 PM ET)
Previous Close$5.18
Today's Range$5.16 - $5.24
52-Week Range$3.30 - $10.10
Volume1,200 shs
Average Volume108,238 shs
Market Capitalization$52.52 million
P/E Ratio-1.80
Dividend YieldN/A
VIVUS logoVIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-10.60
Current Ratio4.93
Quick Ratio4.26


Trailing P/E Ratio-1.80
Forward P/E Ratio-1.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$65.37 million
Price / Sales0.84
Cash FlowN/A
Price / CashN/A
Book Value($0.88) per share
Price / Book-5.89


EPS (Most Recent Fiscal Year)($2.90)
Net Income$-30,510,000.00
Net Margins-72.78%
Return on Equity-843.43%
Return on Assets-14.47%


Outstanding Shares10,650,000
Market Cap$52.52 million

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

When did VIVUS's stock split? How did VIVUS's stock split work?

VIVUS's stock reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.08. The biopharmaceutical company earned $14.96 million during the quarter. VIVUS had a negative net margin of 72.78% and a negative return on equity of 843.43%. View VIVUS's Earnings History.

When is VIVUS's next earnings date?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for VIVUS.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:
  • Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
  • Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
  • Dr. Santosh T. Varghese, Chief Medical Officer (Age 48)
  • Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
  • Mr. John P. Amos, CEO & Director (Age 51)

Has VIVUS been receiving favorable news coverage?

Headlines about VVUS stock have trended somewhat positive on Friday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. VIVUS earned a news impact score of 0.18 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for VIVUS.

Who are VIVUS's major shareholders?

VIVUS's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.79%), BlackRock Inc. (1.93%) and Acadian Asset Management LLC (0.54%). Company insiders that own VIVUS stock include Herm Rosenman, John P Amos, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.

Which institutional investors are selling VIVUS stock?

VVUS stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and BlackRock Inc.. View Insider Buying and Selling for VIVUS.

Which institutional investors are buying VIVUS stock?

VVUS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought VIVUS stock in the last two years include Herm Rosenman and John P Amos. View Insider Buying and Selling for VIVUS.

How do I buy shares of VIVUS?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VVUS stock can currently be purchased for approximately $5.17.

How big of a company is VIVUS?

VIVUS has a market capitalization of $52.52 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. VIVUS employs 52 workers across the globe.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]

MarketBeat Community Rating for VIVUS (NASDAQ VVUS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  351 (Vote Underperform)
Total Votes:  634
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by Staff

Featured Article: NASDAQ

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel